2026-2030年全球新型藥物輸送系統市場

預計從 2025 年到 2030 年，全球新型藥物輸送系統市場規模將成長至 631.305 億美元，預測期內複合年成長率為 4.7%。

本報告對全球新型藥物輸送系統市場進行了全面分析，包括市場規模和預測、趨勢、成長要素、挑戰以及涵蓋約 25 家供應商的供應商分析。

本報告對當前市場狀況、最新趨勢和促進因素以及整體市場環境進行了最新分析。市場成長的促進因素包括生物製藥和新型療法研發管線的擴展、對以患者為中心的護理和自我給藥方式日益重視、技術的持續進步以及跨學科創新。

本研究客觀地結合了一手和二手訊息，包括來自主要行業相關人員的信息。報告內容涵蓋主要公司分析、全面的市場規模資料、細分市場數據及區域分析，以及供應商格局。報告包含歷史數據和預測數據。

本研究指出，將數位健康和​​互聯技術融入藥物輸送裝置是未來幾年全球新型藥物輸送系統市場成長的關鍵促進因素之一。此外，生技藥品和大容量給藥的先進系統的發展，以及奈米技術在標靶和細胞內藥物傳輸領域的廣泛應用，預計也將產生顯著的市場需求。

目錄

第1章：執行摘要

第2章 Technavio 分析

• 分析定價、生命週期、顧客購買籃子、採用率和購買標準。
• 輸入的重要性及差異化因素
• 干擾因素
• 促進因素和挑戰的影響

第3章 市場狀況

• 市場生態系統
• 市場特徵
• 價值鏈分析

第4章 市場規模

• 市場的定義
• 市場區隔分析
• 2025年市場規模
• 市場展望，2025-2030年

第5章 市場規模與表現

• 2020-2024年全球新型藥物輸送系統市場
• 基於應用領域的細分市場分析，2020-2024 年
• 按給藥途徑分類的細分市場分析，2020-2024 年
• 按方法分類的細分市場分析，2020-2024 年
• 區域區隔市場分析，2020-2024 年
• 2020-2024年各國細分市場分析

第6章 定性分析

• 人工智慧的影響：全球藥物輸送系統市場
• 地緣政治衝突對全球新型藥物輸送系統市場的影響。

第7章：五力分析

第8章 市場區隔：按應用

• 比較：按應用
• 腫瘤學
• 神經病學
• 循環系統
• 糖尿病
• 其他
• 市場機會：依應用領域分類

第9章 市場區隔：依給藥途徑

• 比較：按給藥途徑
• 口服藥物遞送系統
• 注射式藥物傳輸系統
• 肺部藥物輸送系統
• 經皮給藥系統
• 其他
• 市場機會：依給藥途徑分類

第10章 市場區隔：依方法

• 比較：依方法
• 標靶藥物遞送系統
• 藥物緩釋系統
• 可調節藥物輸送系統
• 市場機會：依方法

第11章 客戶情況

第12章 區域情勢

• 區域細分
• 區域比較
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞洲
  • 中國
  • 日本
  • 印度
  • 韓國
  • 印尼
  • 泰國
• 世界其他地區（RoW）
  • 巴西
  • 沙烏地阿拉伯
  • UAE
  • 土耳其
  • 南非
  • 阿根廷
  • 以色列
  • 哥倫比亞
• 市場機會：按地區分類

第13章 促進因素、挑戰與機遇

• 市場促進因素
• 市場挑戰
• 促進因素和挑戰的影響
• 市場機遇

第14章 競爭格局

• 概述
• 競爭格局
• 混亂局面
• 產業風險

第15章 競爭分析

• 公司簡介
• 公司排名指標
• 企業市場定位
• 3M Co.
• Abbott Laboratories
• Amgen Inc.
• AptarGroup Inc.
• AstraZeneca Plc
• Becton Dickinson and Co.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Johnson and Johnson
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceutical Ltd.
• West Pharma Services Inc.

第16章附錄

The global new drug delivery systems market is forecasted to grow by USD 63130.5 mn during 2025-2030, accelerating at a CAGR of 4.7% during the forecast period. The report on the global new drug delivery systems market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expanding pipeline of biologic and novel therapeutics, growing emphasis on patient-centric healthcare and self-administration, continuous technological advancements and interdisciplinary innovation.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global new drug delivery systems market is segmented as below:

By Application

• Oncology
• Neurology
• Cardiology
• Diabetes
• Others

By Route Of Administration

• Oral drug delivery systems
• Injectable drug delivery systems
• Pulmonary drug delivery systems
• Transdermal drug delivery systems
• Others

By Method

• Targeted drug delivery systems
• Controlled drug delivery systems
• Modulated drug delivery systems

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the integration of digital health and connectivity in delivery devices as one of the prime reasons driving the global new drug delivery systems market growth during the next few years. Also, development of advanced systems for biologics and large-volume delivery and proliferation of nanotechnology in targeted and cellular delivery will lead to sizable demand in the market.

The report on the global new drug delivery systems market covers the following areas:

• Global new drug delivery systems market sizing
• Global new drug delivery systems market forecast
• Global new drug delivery systems market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global new drug delivery systems market vendors that include 3M Co., Abbott Laboratories, Amgen Inc., AptarGroup Inc., AstraZeneca Plc, Baxter International Inc., Bayer AG, Becton Dickinson and Co., Boston Scientific Corp., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gerresheimer AG, GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Ltd., West Pharma Services Inc.. Also, the global new drug delivery systems market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Method
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global New Drug Delivery Systems Market 2020 - 2024
  • Historic Market Size - Data Table on Global New Drug Delivery Systems Market 2020 - 2024 ($ million)
• 5.2 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.3 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.4 Method segment analysis 2020 - 2024
  • Historic Market Size - Method Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global New Drug Delivery Systems Market
• 6.2 Impact of Geopolitical Conflicts on Global New Drug Delivery Systems Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Application

• 8.1 Market segments
• 8.2 Comparison by Application
• 8.3 Oncology - Market size and forecast 2025-2030
• 8.4 Neurology - Market size and forecast 2025-2030
• 8.5 Cardiology - Market size and forecast 2025-2030
• 8.6 Diabetes - Market size and forecast 2025-2030
• 8.7 Others - Market size and forecast 2025-2030
• 8.8 Market opportunity by Application
  • Market opportunity by Application ($ million)

9 Market Segmentation by Route of Administration

• 9.1 Market segments
• 9.2 Comparison by Route of Administration
• 9.3 Oral drug delivery systems - Market size and forecast 2025-2030
• 9.4 Injectable drug delivery systems - Market size and forecast 2025-2030
• 9.5 Pulmonary drug delivery systems - Market size and forecast 2025-2030
• 9.6 Transdermal drug delivery systems - Market size and forecast 2025-2030
• 9.7 Others - Market size and forecast 2025-2030
• 9.8 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

10 Market Segmentation by Method

• 10.1 Market segments
• 10.2 Comparison by Method
• 10.3 Targeted drug delivery systems - Market size and forecast 2025-2030
• 10.4 Controlled drug delivery systems - Market size and forecast 2025-2030
• 10.5 Modulated drug delivery systems - Market size and forecast 2025-2030
• 10.6 Market opportunity by Method
  • Market opportunity by Method ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 South Africa - Market size and forecast 2025-2030
  • 12.6.6 Argentina - Market size and forecast 2025-2030
  • 12.6.7 Israel - Market size and forecast 2025-2030
  • 12.6.8 Colombia - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Expanding pipeline of biologic and novel therapeutics
  • Growing emphasis on patient-centric healthcare and self-administration
  • Continuous technological advancements and interdisciplinary innovation
• 13.2 Market challenges
  • Navigating complex and stringent regulatory landscape
  • Prohibitive development costs and inherent technical complexity
  • Securing favorable reimbursement and demonstrating clear value proposition
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Integration of digital health and connectivity in delivery devices
  • Development of advanced systems for biologics and large-volume delivery
  • Proliferation of nanotechnology in targeted and cellular delivery

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 3M Co.
  • 3M Co. - Overview
  • 3M Co. - Business segments
  • 3M Co. - Key news
  • 3M Co. - Key offerings
  • 3M Co. - Segment focus
  • SWOT
• 15.5 Abbott Laboratories
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key news
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Segment focus
  • SWOT
• 15.6 Amgen Inc.
  • Amgen Inc. - Overview
  • Amgen Inc. - Product / Service
  • Amgen Inc. - Key offerings
  • SWOT
• 15.7 AptarGroup Inc.
  • AptarGroup Inc. - Overview
  • AptarGroup Inc. - Business segments
  • AptarGroup Inc. - Key news
  • AptarGroup Inc. - Key offerings
  • AptarGroup Inc. - Segment focus
  • SWOT
• 15.8 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Business segments
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Segment focus
  • SWOT
• 15.9 Becton Dickinson and Co.
  • Becton Dickinson and Co. - Overview
  • Becton Dickinson and Co. - Business segments
  • Becton Dickinson and Co. - Key offerings
  • Becton Dickinson and Co. - Segment focus
  • SWOT
• 15.10 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key offerings
  • SWOT
• 15.11 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.12 Johnson and Johnson
  • Johnson and Johnson - Overview
  • Johnson and Johnson - Business segments
  • Johnson and Johnson - Key news
  • Johnson and Johnson - Key offerings
  • Johnson and Johnson - Segment focus
  • SWOT
• 15.13 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 15.14 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.15 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.16 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 15.17 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.18 West Pharma Services Inc.
  • West Pharma Services Inc. - Overview
  • West Pharma Services Inc. - Business segments
  • West Pharma Services Inc. - Key offerings
  • West Pharma Services Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations